A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: WJB001 Capsules+Paclitaxel/Paclitaxel-albuminDrug: WJB001 Capsules+carboplatin/NedaplatinDrug: WJB001 Capsules+Paclitaxel+carboplatinDrug: WJB001 Capsules+NiraparibDrug: WJB001 Capsules+Bevacizumab
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 86
- Registration Number
- NCT06953323
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2025-02-10
- Target Recruit Count
- 210
- Registration Number
- NCT05773820
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Tumor Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
© Copyright 2025. All Rights Reserved by MedPath